Rheumatology (Oxford, England) · 2026
DNA hypo-methylation of the TNFA gene predicts response to MTX in RA but not in PsA.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dalix Elisa, Pitaksalee Rujiraporn, De Marco Gabriele, Parmar Rekha, Sargent Thomas, Ng Helen, Shuweihdi Farag, Kingsbury Sarah R, Marzo-Ortega Helena, Conaghan Philip G, Emery Paul, Marotte Hubert, Ponchel Frederique
Аннотация
OBJECTIVES: The 'Treat-to-Target' approach significantly improves treatment outcomes in RA and PsA (RA/PsA). MTX is commonly used as a first-line treatment upon diagnosis. However, 50-70% of treated patients do not achieve clinical remission after 6 months. We previously developed a quantitative methylation-sensitive qPCR (qMSP) assay to quantify DNA-methylation levels of the TNFA gene. We demonstrated its predictive value for RA diagnosis. Here, we assessed the utility of this qMSP assay for predicting MTX treatment outcome and investigated changes in DNA-methylation levels after 6 months of MTX.
METHODS: Early untreated RA (n = 201) and PsA (n = 77) were included with healthy controls (n = 39). The TNFA-qMSP assay was performed by qPCR on bisulphite-converted DNA extracted from frozen peripheral blood mononuclear cells. The outcome predictive-value of DNA-methylation levels was analysed using binary logistic regression and area under the curve (AUC).
RESULTS: Pre-treatment DNA-methylation levels of the TNFA gene were reduced in RA (P = 1.8 × 10-13) and PsA (P = 0.007) compared with controls. Higher DNA-methylation levels were associated with MTX-induced remission in RA (AUC = 0.721) and substantially improved the performance of a predictive model when combined with clinical data (AUC = 0.760) compared with clinical data only (AUC = 0.699). Levels of methylation reduced over time, irrespective of response to MTX in RA. In PsA, DNA-methylation levels were not associated with treatment outcome.
CONCLUSION: The TNF qMSP assay has potential clinical utility as a biomarker for predicting MTX-induced remission specifically in early RA, but not in PsA. However, MTX does not appear to prevent the reduction of DNA-methylation levels at the TNFA loci over time.
METHODS: Early untreated RA (n = 201) and PsA (n = 77) were included with healthy controls (n = 39). The TNFA-qMSP assay was performed by qPCR on bisulphite-converted DNA extracted from frozen peripheral blood mononuclear cells. The outcome predictive-value of DNA-methylation levels was analysed using binary logistic regression and area under the curve (AUC).
RESULTS: Pre-treatment DNA-methylation levels of the TNFA gene were reduced in RA (P = 1.8 × 10-13) and PsA (P = 0.007) compared with controls. Higher DNA-methylation levels were associated with MTX-induced remission in RA (AUC = 0.721) and substantially improved the performance of a predictive model when combined with clinical data (AUC = 0.760) compared with clinical data only (AUC = 0.699). Levels of methylation reduced over time, irrespective of response to MTX in RA. In PsA, DNA-methylation levels were not associated with treatment outcome.
CONCLUSION: The TNF qMSP assay has potential clinical utility as a biomarker for predicting MTX-induced remission specifically in early RA, but not in PsA. However, MTX does not appear to prevent the reduction of DNA-methylation levels at the TNFA loci over time.